Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005. What Are ...

Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. The biotech industry has been a robust roller-coaster ...

XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% ...

VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors.

The Direxion Daily S&P Biotech Bear 3X Shares ETF offers -3X daily leverage to the S&P Biotechnology Select Industry Index, primarily attracting short-term traders. LABD has lost 99.98% of its value ...

The biotechnology sector continued its advance on Tuesday, with the iShares Biotechnology ETF (IBB) reaching a record intraday high of $179.95 as investor interest in the industry remained strong. The ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.